El polimorfismo K153R del gen de la miostatina como gen candidato en la longevidad extrema de centenarias españolas

  1. Nuria Garatachea 1
  2. G. Rodríguez-Romo 2
  3. A. Santos-Lozano 3
  4. C. Santiago-Dorrego 4
  5. T. Yvert 4
  6. C. Fiuza-Luce 5
  7. A. Lucia 5
  1. 1 Universidad de Zaragoza, España
  2. 2 Universidad Politécnica de Madrid
    info

    Universidad Politécnica de Madrid

    Madrid, España

    ROR https://ror.org/03n6nwv02

  3. 3 Universidad de León, España
  4. 4 Universidad Europea de Madrid, España
  5. 5 Hospital Universitario 12 de Octubre, Madrid, España
Zugehörigkeit anzeigen +
Zeitschrift:
Kronos: revista universitaria de la actividad física y el deporte

ISSN: 1579-5225

Datum der Publikation: 2014

Ausgabe: 13

Nummer: 2

Art: Artikel

DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Kronos: revista universitaria de la actividad física y el deporte

Zusammenfassung

The myostatin (MSTN) gene is a candidate to influence extreme longevity owing to its role in modulating muscle mass and sarcopenia, and especially in inhibiting the main nutrient-sensing pathway involved in longevity, i.e. mTOR (mammalian target-of-rapamycin). We compared allele/genotype distributions of the exonic MSTN variants K153R (rs1805086), E164K (rs35781413), I225T and P198A, in women centenarians (cases, n=132; age range: 100-107 years) and younger women adults (controls, n=167; age < 50 years). The frequency of the variant R-allele and of R-allele carriers was significantly higher in centenarians (6.8% and 12.1%) than in controls (1.5% and 3.8%) (p=0.0008 and p=0.0022 respectively). The odds ratio (OR) of being a centenarian if the subject had the R allele was 4.47 (95% confidence interval (CI): 1.59-12.54 p=0.004), compared to the control group. Although more research is needed, the variant allele of the MSTN K153R polymorphism could be among the genetic contributors associated with exceptional longevity.

Bibliographische Referenzen

  • 1. Baumann, A. P., Ibebunjo, C., Grasser, W. A., & Paralkar, V. M. (2003). Myostatin expression in age and denervation-induced skeletal muscle atrophy. Journal of musculoskeletal & neuronal interactions, 3(1), 8-16.
  • 2. Bjedov, I., & Partridge, L. (2011). A longer and healthier life with TOR down-regulation: genetics and drugs. Biochemical Society transactions, 39(2), 460-465. doi: 10.1042/BST0390460
  • 3. Carlson, C. J., Booth, F. W., & Gordon, S. E. (1999). Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. The American journal of physiology, 277(2 Pt 2), R601-606.
  • 4. Constantin, D., McCullough, J., Mahajan, R. P., & Greenhaff, P. L. (2011). Novel events in the molecular regulation of muscle mass in critically ill patients. The Journal of physiology, 589(Pt 15), 3883-3895. doi: 10.1113/jphysiol.2011.206193
  • 5. Corsi, A. M., Ferrucci, L., Gozzini, A., Tanini, A., & Brandi, M. L. (2002). Myostatin polymorphisms and age-related sarcopenia in the Italian population. J Am Geriatr Soc, 50(8), 1463. doi: jgs50376 [pii]
  • 6. Chanock, S. J., Manolio, T., Boehnke, M., Boerwinkle, E., Hunter, D. J., Thomas, G., . . . Collins, F. S. (2007). Replicating genotype-phenotype associations. Nature, 447(7145), 655-660. doi: 447655a [pii] 10.1038/447655a
  • 7. Dasarathy, S., Dodig, M., Muc, S. M., Kalhan, S. C., & McCullough, A. J. (2004). Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. American journal of physiology. Gastrointestinal and liver physiology, 287(6), G1124-1130. doi: 10.1152/ajpgi.00202.2004
  • 8. Fenton, T. R., & Gout, I. T. (2011). Functions and regulation of the 70kDa ribosomal S6 kinases. The international journal of biochemistry & cell biology, 43(1), 47-59. doi: 10.1016/j.biocel.2010.09.018
  • 9. Ferrell, R. E., Conte, V., Lawrence, E. C., Roth, S. M., Hagberg, J. M., & Hurley, B. F. (1999). Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle-related phenotypes. Genomics, 62(2), 203-207. doi: 10.1006/geno.1999.5984 S0888-7543(99)95984-0 [pii]
  • 10. Fontana, L., Partridge, L., & Longo, V. D. (2010). Extending healthy life span--from yeast to humans. Science, 328(5976), 321-326. doi: 10.1126/science.1172539
  • 11. Garatachea, N., & Lucia, A. (2011). Genes and the ageing muscle: a review on genetic association studies. Age (Dordr). doi: 10.1007/s11357-011-9327-0
  • 12. Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Bhasin, S. (1998). Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proceedings of the National Academy of Sciences of the United States of America, 95(25), 14938-14943.
  • 13. Gonzalez-Freire, M., Rodriguez-Romo, G., Santiago, C., Bustamante-Ara, N., Yvert, T., Gomez-Gallego, F., . . . Lucia, A. (2010). The K153R variant in the myostatin gene and sarcopenia at the end of the human lifespan. Age (Dordr), 32(3), 405-409. doi: 10.1007/s11357-010-9139-7
  • 14. Huygens, W., Thomis, M. A., Peeters, M. W., Aerssens, J., Janssen, R., Vlietinck, R. F., & Beunen, G. (2004). Linkage of myostatin pathway genes with knee strength in humans. Physiol Genomics, 17(3), 264-270. doi: 10.1152/physiolgenomics.00224.2003 00224.2003 [pii]
  • 15. Jiang, M. S., Liang, L. F., Wang, S., Ratovitski, T., Holmstrom, J., Barker, C., & Stotish, R. (2004). Characterization and identification of the inhibitory domain of GDF-8 propeptide. Biochem Biophys Res Commun, 315(3), 525-531. doi: 10.1016/j.bbrc.2004.01.085 S0006291X04001391 [pii]
  • 16. Kawada, S., Tachi, C., & Ishii, N. (2001). Content and localization of myostatin in mouse skeletal muscles during aging, mechanical unloading and reloading. Journal of muscle research and cell motility, 22(8), 627-633.
  • 17. Kenyon, C. J. (2010). The genetics of ageing. Nature, 464(7288), 504-512. doi: 10.1038/nature08980
  • 18. Krivickas, L. S., Walsh, R., & Amato, A. A. (2009). Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve, 39(1), 3-9. doi: 10.1002/mus.21200
  • 19. Lawlor, M. W., Read, B. P., Edelstein, R., Yang, N., Pierson, C. R., Stein, M. J., . . . Beggs, A. H. (2011). Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice. The American journal of pathology, 178(2), 784-793. doi: 10.1016/j.ajpath.2010.10.035
  • 20. Lee, S. J., & McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A, 98(16), 9306-9311. doi: 10.1073/pnas.151270098 151270098 [pii]
  • 21. Lee, S. J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E., Tomkinson, K. N., . . . Wolfman, N. M. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences of the United States of America, 102(50), 18117-18122. doi: 10.1073/pnas.0505996102
  • 22. Lipina, C., Kendall, H., McPherron, A. C., Taylor, P. M., & Hundal, H. S. (2010). Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice. FEBS letters, 584(11), 2403-2408. doi: 10.1016/j.febslet.2010.04.039
  • 23. Martin, G. M., Bergman, A., & Barzilai, N. (2007). Genetic determinants of human health span and life span: progress and new opportunities. PLoS genetics, 3(7), e125. doi: 10.1371/journal.pgen.0030125
  • 24. McPherron, A. C., Lawler, A. M., & Lee, S. J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387(6628), 83-90. doi: 10.1038/387083a0
  • 25. McPherron, A. C., & Lee, S. J. (1997). Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A, 94(23), 12457-12461.
  • 26. Metter, E. J., Talbot, L. A., Schrager, M., & Conwit, R. A. (2004). Arm-cranking muscle power and arm isometric muscle strength are independent predictors of all-cause mortality in men. Journal of applied physiology, 96(2), 814-821. doi: 10.1152/japplphysiol.00370.2003
  • 27. Morissette, M. R., Stricker, J. C., Rosenberg, M. A., Buranasombati, C., Levitan, E. B., Mittleman, M. A., & Rosenzweig, A. (2009). Effects of myostatin deletion in aging mice. Aging cell, 8(5), 573-583. doi: 10.1111/j.1474-9726.2009.00508.x
  • 28. Morrison, B. M., Lachey, J. L., Warsing, L. C., Ting, B. L., Pullen, A. E., Underwood, K. W., . . . Wagner, K. R. (2009). A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Experimental neurology, 217(2), 258-268. doi: 10.1016/j.expneurol.2009.02.017
  • 29. Murphy, K. T., Ryall, J. G., Snell, S. M., Nair, L., Koopman, R., Krasney, P. A., . . . Lynch, G. S. (2010). Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice. The American journal of pathology, 176(5), 2425-2434. doi: 10.2353/ajpath.2010.090932
  • 30. Rose, F. F., Jr., Mattis, V. B., Rindt, H., & Lorson, C. L. (2009). Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Human molecular genetics, 18(6), 997-1005. doi: 10.1093/hmg/ddn426
  • 31. Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010). Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Molecular cell, 40(2), 310-322. doi: 10.1016/j.molcel.2010.09.026
  • 32. Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. American journal of physiology. Cell physiology, 296(6), C1258-1270. doi: 10.1152/ajpcell.00105.2009
  • 33. Tsuchida, K. (2008). Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases, 27, 14-18.
  • 34. Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Mendell, J. R. (2008). A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol, 63(5), 561-571. doi: 10.1002/ana.21338
  • 35. Yarasheski, K. E., Bhasin, S., Sinha-Hikim, I., Pak-Loduca, J., & Gonzalez-Cadavid, N. F. (2002). Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging, 6(5), 343-348.
Fuente de los datos: Dialnet